ip

IP7e (isoxazolo-pyridinone 7e) is a Nurr1 activator with an EC50 value of 3.9 nM.

IP7 is a diphosphoinositol pentakisphosphate regioisomer.

RO3244794 is a selective prostacyclin (IP) receptor antagonist that can be used to study liver injury.

Anisotropine Methylbromide is an anticholinergic agent and has been used for relief of gastrointestinal spasm and for the suppression of gastric acid secretion.

Treprostinil (Orenitram) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).

Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).

Treprostinil diethanolamine (UT-15C) is a potent agonist of EP2, DP1, and IP, with values of 3.6, 4.4, and 32.1 nM for EP2, DP1, and IP, respectively, and 212, 826, 2505, and 4680 nM for EP1, EP4, EP3, and FPKi, respectively. Treprostinil diethanolamine contributes to the upregulation of cAMP, maintaining vascular homeostasis and causing vasodilation in human pulmonary arteries.

Tetrahexyldecyl ascorbate (BV-OSC) is a lipophilic precursor of ascorbic acid, a more stable and permeable form of vitamin C. It is a potent anti-photo-aging and anti-hyperpigmentation antioxidant that inhibits MMP enzyme activity.

MRT-10 is a Smoothened (Smo) receptor antagonist.

1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist known for its anti-tumor properties.

KAG-308 is an effective selective and orally active agonist of the EP4 receptor (Ki: 2.57 nM and EC50: 17 nM for human EP4 receptor), more selective over EP1, EP2, EP3, and IP receptor. KAG-308 suppresses colitis and promotes histological mucosal healing,

L 888607 is an effective and selective CRTH2 agonist (Ki: 0.8 nM).

NI-0801 (Anti-CXCL10 / IP-1) is a CHO-expressed humanized monoclonal antibody targeting CXCL10/IP-10 for the study of vitiligo and biliary cirrhosis.

IP-DNQ is a potent NQO1-dependent cytotoxin. It exhibits strong cytotoxic activity against MCF-7 cells, with an IC50 of 0.18 µM. This compound is applicable for cancer research.

IP-66 is a potent postsynaptic alpha receptor antagonist, which can be utilized in cardiovascular disease research, including hypertension studies.

IPreceptor agonist 1 (compound 6c-14S) is an orally active IP receptor agonist with an IC50 value of 0.15 μM, capable of inhibiting ADP (300 μM) induced platelet aggregation in rabbit platelet plasma. This compound is used in research related to pulmonary arterial hypertension.

CAY10449 is an antagonist of the I prostanoid receptor. It is capable of reversing the decrease in transepithelial electrical resistance (TEER) induced by iloprost. Additionally, CAY10449 can counteract the effects of ONO-1301 in mouse models. This compound is useful for research in asthma and allergic airway inflammation.

CI-IP3 /PM is a cell-permeable caged inositol triphosphate that promotes the release of Ca2+ from internal storage under UV photolysis.

iP300v is a negative control for iP300w

IP6K2-IN-2 is an IP6K2 inhibitor with IC₅₀ values of 0.58 μM, 0.86 μM, and 3.08 μM for IP6K2, IP6K1, and IP6K3, respectively. It can be used in obesity research.

IP6K-IN-1 is a potent and selective IP6K inhibitor with an IC₅₀ of 0.896 μM, applicable to research on metabolic diseases.

iP300w (Compound 9) is an inhibitor of the histone acetyltransferase p300 (KAT3B). It is applicable in the synthesis of PROTACBT-O2C.

IP2, an immunomodulatory agent, enhances PTP (Pioneer Translation Product)-derived antigen presentation in cancer cells without exhibiting cytotoxicity. Additionally, IP2 has been shown to induce tumor growth defects in mouse models [1].

IP6K2-IN-1 (Compd 20s) acts as a selective inhibitor of IP6K2, exhibiting an IC50 value of 0.55 μM [1].